Population-Based Clinical Cancer Registration in Germany.
Germany
benchmarking
cancer
cancer registration
incidence
quality assurance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
01
07
2023
revised:
26
07
2023
accepted:
31
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
In 2013, a new federal law obligated all German federal states to collect additional clinical data in population-based cancer registries as an active tool for monitoring and improving the quality of cancer care, increasing transparency and promoting health research. Now, 10 years later, the current status of the expanded cancer registration is presented, including current figures on cancer in Germany. Reporting of cancer is mandatory for physicians, and about 5 to 10 reports from different healthcare providers are expected for each case. A uniform national dataset of about 130 items is used, and reports are usually sent electronically to the registry. We used the most recent data available from cancer registries up to the year of diagnosis in 2019. We calculated incidence rates and 5-year relative survival (5YRS) for common cancers. Data on clinical outcomes and benchmarking based on quality indicators (QIs) from guidelines were provided by the Cancer Registry Schleswig-Holstein (CR SH). All federal state cancer registries met most of the previously defined national eligibility criteria. Approximately 505,000 cancer cases were registered in 2019, with breast, prostate, colorectal and lung cancer being the most common cancers. The age-standardised cancer incidence has slightly decreased during the last decade. and spatial heterogeneity can be observed within Germany. 5YRS for all cancers was 67% and 63% for women and men, respectively. Therapy data for rectal cancer in 2019-2021 from the CR SH are shown as an example: 69% of the registered patients underwent surgery, mostly with curative intent (84%) and tumour-free resection (91%). Radiotherapy was given to 33% of the patients, and chemotherapy was given to 40%. Three selected QIs showed differences between involved healthcare providers. The implementation of population-based clinical cancer registration can be considered a success. Comprehensive recording of diagnosis, treatment and disease progression and the use of registry data for quality assurance, benchmarking and feedback have been implemented.
Identifiants
pubmed: 37568750
pii: cancers15153934
doi: 10.3390/cancers15153934
pmc: PMC10416989
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Methods Inf Med. 2009;48(2):123-8
pubmed: 19283308
Eur J Cancer. 2015 Jun;51(9):1039-49
pubmed: 25131265
Int J Gynecol Cancer. 2023 Apr 3;33(4):534-542
pubmed: 36581486
Z Evid Fortbild Qual Gesundhwes. 2015;109(6):452-8
pubmed: 26474650
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Jan;57(1):7-12
pubmed: 24357166
Eur J Cardiothorac Surg. 2021 Jan 4;59(1):92-99
pubmed: 32728711
Eur Urol. 2017 Sep;72(3):379-386
pubmed: 28511884
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Dec;60(12):1319-1327
pubmed: 29063158
Eur J Cancer. 2017 Nov;85:15-22
pubmed: 28881247
Gynecol Oncol. 2023 Jul;174:89-97
pubmed: 37167897
Eur J Cancer Prev. 2017 Sep;26 Joining forces for better cancer registration in Europe:S132-S138
pubmed: 28639952
J Health Monit. 2023 Jun 14;8(2):79-94
pubmed: 37408714
Front Oncol. 2023 Feb 08;13:1109978
pubmed: 36845700
Value Health. 2020 Sep;23(9):1191-1199
pubmed: 32940237
J Registry Manag. 2014 Spring;41(1):31-7
pubmed: 24893186
Eur J Surg Oncol. 2021 Nov;47(11):2821-2829
pubmed: 34120807